Javascript must be enabled to continue!
New Functional Food for the Treatment of Gastric Ulcer Based on Bioadhesive Microparticles Containing Sage Extract: Anti-Ulcerogenic, Anti-Helicobacter pylori, and H+/K+-ATPase-Inhibiting Activity Enhancement
View through CrossRef
Salvia officinalis is an aromatic plant of Mediterranean origin traditionally used to treat inflammatory, cardiovascular, endocrine, and digestive diseases. In this work, the ability of the Salvia officinalis extract in the treatment of gastric ulcers was evaluated, and an innovative administration system was proposed to increase the therapeutic effect of this plant. Salvia officinalis ethanolic extract was prepared and analyzed by HPLC/UV-DAD and encapsulated in a matrix based on gelatin and pectin using an emulsion–coacervation process. The prepared microcapsules were analyzed by laser particle size, optical microscopy, in vitro dissolution kinetics, and ex vivo bioadhesion. In order to determine the action mechanism of Salvia officinalis extract, in the treatment of gastric ulcer, the in vivo anti-ulcerogenic activity in rats, using the ulcer model induced by ethanol; the in vivo anti-Helicobacter pylori activity; and in vitro inhibitory activity of H+/K+-ATPase were carried out. These three biological activities were evaluated for ethanolic extract and microcapsules to determine the effect of formulation on biological activities. Ethanolic extract of Salvia officinalis was mainly composed of polyphenols (chlorogenic acid 7.43%, rutin 21.74%, rosmarinic acid 5.88%, and quercitrin 14.39%). Microencapsulation of this extract allowed us to obtain microcapsules of 104.2 ± 7.5 µm in diameter, an encapsulation rate of 96.57 ± 3.05%, and adequate bioadhesion. The kinetics of in vitro dissolution of the extract increase significantly after its microencapsulation. Percentages of ulcer inhibition for 100 mg/kg of extract increase from 71.71 ± 2.43% to 89.67 ± 2.54% after microencapsulation. In vitro H+/K+-ATPase-inhibiting activity resulted in an IC50 of 86.08 ± 8.69 µM/h/mg protein for free extract and 57.43 ± 5.78 µM/h/mg protein for encapsulated extract. Anti-Helicobacter pylori activity showed a similar Minimum Inhibitory Concentration (MIC) of 50 µg/mL for the extract and microcapsules. Salvia officinalis ethanolic extract has a significant efficacy for the treatment of gastric ulcer; its mechanism of action is based on its gastroprotective effect, anti-Helicobacter pylori, and H+/K+-ATPase inhibitor. Moreover, the microencapsulation of this extract increases its gastroprotective and H+/K+-ATPase-inhibiting activities significantly.
Title: New Functional Food for the Treatment of Gastric Ulcer Based on Bioadhesive Microparticles Containing Sage Extract: Anti-Ulcerogenic, Anti-Helicobacter pylori, and H+/K+-ATPase-Inhibiting Activity Enhancement
Description:
Salvia officinalis is an aromatic plant of Mediterranean origin traditionally used to treat inflammatory, cardiovascular, endocrine, and digestive diseases.
In this work, the ability of the Salvia officinalis extract in the treatment of gastric ulcers was evaluated, and an innovative administration system was proposed to increase the therapeutic effect of this plant.
Salvia officinalis ethanolic extract was prepared and analyzed by HPLC/UV-DAD and encapsulated in a matrix based on gelatin and pectin using an emulsion–coacervation process.
The prepared microcapsules were analyzed by laser particle size, optical microscopy, in vitro dissolution kinetics, and ex vivo bioadhesion.
In order to determine the action mechanism of Salvia officinalis extract, in the treatment of gastric ulcer, the in vivo anti-ulcerogenic activity in rats, using the ulcer model induced by ethanol; the in vivo anti-Helicobacter pylori activity; and in vitro inhibitory activity of H+/K+-ATPase were carried out.
These three biological activities were evaluated for ethanolic extract and microcapsules to determine the effect of formulation on biological activities.
Ethanolic extract of Salvia officinalis was mainly composed of polyphenols (chlorogenic acid 7.
43%, rutin 21.
74%, rosmarinic acid 5.
88%, and quercitrin 14.
39%).
Microencapsulation of this extract allowed us to obtain microcapsules of 104.
2 ± 7.
5 µm in diameter, an encapsulation rate of 96.
57 ± 3.
05%, and adequate bioadhesion.
The kinetics of in vitro dissolution of the extract increase significantly after its microencapsulation.
Percentages of ulcer inhibition for 100 mg/kg of extract increase from 71.
71 ± 2.
43% to 89.
67 ± 2.
54% after microencapsulation.
In vitro H+/K+-ATPase-inhibiting activity resulted in an IC50 of 86.
08 ± 8.
69 µM/h/mg protein for free extract and 57.
43 ± 5.
78 µM/h/mg protein for encapsulated extract.
Anti-Helicobacter pylori activity showed a similar Minimum Inhibitory Concentration (MIC) of 50 µg/mL for the extract and microcapsules.
Salvia officinalis ethanolic extract has a significant efficacy for the treatment of gastric ulcer; its mechanism of action is based on its gastroprotective effect, anti-Helicobacter pylori, and H+/K+-ATPase inhibitor.
Moreover, the microencapsulation of this extract increases its gastroprotective and H+/K+-ATPase-inhibiting activities significantly.
Related Results
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
The role of helicobacter pylori in coronary heart disease : laboratory, observational, and interventional studies
<p dir="ltr"><b>Background</b></p><p dir="ltr">Helicobacter pylori (H. pylori) infects nearly half of the world's population and causes gastritis, pep...
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
THE CLINICAL CHARACTERISTICS, ENDOSCOPIC FINDINGS AND THE EFFICACY OF THE BISMUTH-CONTAINING QUADRUPLE REGIMEN INTREATMENT OF PATIENTS WITH HELICOBACTER PYLORIGASTRODUODENAL INFLAMMATORY AND ULCER AT CAN THO HOSPITAL OF UNIVERSITY OF MEDICINE AND PHARMACY
Background: Helicobacter pylori causes inflammation of the gastric mucosa and is associated with many upper gastrointestinal diseases, including chronic gastritis, peptic ulcer dis...
Association of Helicobacter pylori Infection with Severity and Clinical Presentation of Gastric Ulcer: A Cross-Sectional Clinical Study
Association of Helicobacter pylori Infection with Severity and Clinical Presentation of Gastric Ulcer: A Cross-Sectional Clinical Study
Background: Helicobacter pylori infection is a major etiological factor in gastric ulcer disease and is associated with variations in symptom severity and ulcer morphology. Underst...
Anti-ulcerogenic Activity of the Fractions of Methanol Leaves Extract of Hannoa Klaineana in Wistar Rats
Anti-ulcerogenic Activity of the Fractions of Methanol Leaves Extract of Hannoa Klaineana in Wistar Rats
Nowadays, search for medicinal plants with anti-ulcerogenic activity has been increased due to their negligible side effects compared to synthetic drugs. Hannoa klaineana Pierre &a...
Gastric Pyloric Schwannoma: A Case Report and Review of the Literature
Gastric Pyloric Schwannoma: A Case Report and Review of the Literature
Abstract
Introduction
Schwannomas are slow-growing, subclinical neoplasms rarely found in the gastrointestinal tract. This study reports a schwannoma in the pyloric region of the s...
Evaluation of H. pylori - Eradication Triple Therapy in Iraqi Peptic Ulcer Patients according to ABO Phenotypes: a New Study
Evaluation of H. pylori - Eradication Triple Therapy in Iraqi Peptic Ulcer Patients according to ABO Phenotypes: a New Study
Infection with H. pylori is an up growing public health problem that affects approximately 50% of people in industrialized nations, and up to 80% in developing countries. Helicoba...
Helicobacter pylori and gastric cancer
Helicobacter pylori and gastric cancer
Introduction: According to GLOBOCAN estimates for 2018, gastric cancer was the fifth most common cancer and the third most common cause of death from malignant diseases in the worl...

